Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

PMID:
30536609
2.

Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.

Orsaria P, Chiaravalloti A, Caredda E, Marchese PV, Titka B, Anemona L, Portarena I, Schillaci O, Petrella G, Palombi L, Buonomo OC.

Anticancer Res. 2018 Dec;38(12):6639-6652. doi: 10.21873/anticanres.13031. Erratum in: Anticancer Res. 2019 Jan;39(1):527.

PMID:
30504372
3.

Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer.

Ferroni P, Roselli M, Buonomo OC, Spila A, Portarena I, Laudisi A, Valente MG, Pirillo SP, Fortunato L, Costarelli L, Cavaliere F, Guadagni F.

Anticancer Res. 2018 Aug;38(8):4705-4712. doi: 10.21873/anticanres.12777.

PMID:
30061239
4.

Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.

Formica V, Benassi M, Del Vecchio Blanco G, Doldo E, Martano L, Portarena I, Nardecchia A, Lucchetti J, Morelli C, Giudice E, Rossi P, Anselmo A, Sileri P, Sica G, Orlandi A, Santoni R, Roselli M.

Med Oncol. 2018 May 2;35(6):83. doi: 10.1007/s12032-018-1141-4.

PMID:
29721745
5.

Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.

Orsaria P, Caredda E, Genova F, Materazzo M, Capuano I, Vanni G, Granai AV, DE Majo A, Portarena I, Sileri P, Petrella G, Palombi L, Buonomo OC.

Anticancer Res. 2018 Apr;38(4):2109-2117.

PMID:
29599329
6.

New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.

Buonomo OC, Caredda E, Portarena I, Vanni G, Orlandi A, Bagni C, Petrella G, Palombi L, Orsaria P.

PLoS One. 2017 Sep 18;12(9):e0184680. doi: 10.1371/journal.pone.0184680. eCollection 2017.

7.

Functional impairment of activated protein C in breast cancer - relationship to survival outcomes.

Roselli M, Ferroni P, Riondino S, Mariotti S, Portarena I, Alessandroni J, Ialongo C, Massoud R, Costarelli L, Cavaliere F, Bernardini S, Guadagni F.

Am J Cancer Res. 2016 Jun 1;6(6):1450-7. eCollection 2016.

8.

Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.

Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M.

Oncologist. 2016 Sep;21(9):1041-9. doi: 10.1634/theoncologist.2015-0462. Epub 2016 Jul 7.

9.

Current challenges in HER2-positive breast cancer.

Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, Moscetti L, Portarena I, Rossi E, Marchetti P.

Crit Rev Oncol Hematol. 2016 Feb;98:211-21. doi: 10.1016/j.critrevonc.2015.10.016. Epub 2015 Oct 31. Review.

PMID:
26638862
10.

Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass.

Del Vecchio Blanco G, Coppola M, Mannisi E, Bevivino G, Formica V, Portarena I, Romeo S, Sileri P, Roselli M, Pallone F, Paoluzi OA.

Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1045-51. doi: 10.1097/MEG.0000000000000390.

PMID:
26011232
11.

Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy.

Ferroni P, Guadagni F, Riondino S, Portarena I, Mariotti S, La Farina F, Davì G, Roselli M.

Haematologica. 2014 Oct;99(10):1638-44. doi: 10.3324/haematol.2014.109470. Epub 2014 Aug 1.

12.

Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.

Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F.

Anticancer Res. 2014 Mar;34(3):1153-61.

PMID:
24596353
13.

Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients.

Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, Formica V, Vergati M, Guadagni F.

Thromb Haemost. 2012 Dec;108(6):1243-5. doi: 10.1160/TH12-06-0418. Epub 2012 Oct 10. No abstract available.

PMID:
23052961
14.

Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.

Ferroni P, Martini F, Portarena I, Massimiani G, Riondino S, La Farina F, Mariotti S, Guadagni F, Roselli M.

Clin Lung Cancer. 2012 Nov;13(6):482-7. doi: 10.1016/j.cllc.2012.03.005. Epub 2012 May 15.

PMID:
22591606
15.

Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.

Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, Massimiani G, Palmirotta R, Guadagni F, Roselli M.

Int J Colorectal Dis. 2012 Dec;27(12):1561-7. doi: 10.1007/s00384-012-1493-8. Epub 2012 May 12.

PMID:
22581210
16.

Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study.

Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Guadagni F, Roselli M.

Support Care Cancer. 2012 Nov;20(11):2713-20. doi: 10.1007/s00520-012-1391-1. Epub 2012 Feb 10.

PMID:
22322591
17.

An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients.

Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Roselli M, Guadagni F.

Thromb Haemost. 2011 May;105(5):931-2. doi: 10.1160/TH10-11-0757. Epub 2011 Feb 28. No abstract available.

PMID:
21359410
18.

Caregiver distress in the early phases of cancer.

Pellegrino R, Formica V, Portarena I, Mariotti S, Grenga I, Del Monte G, Roselli M.

Anticancer Res. 2010 Nov;30(11):4657-63.

PMID:
21115920
19.

Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients.

Ferroni P, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirotta R, Buonomo O, Petrella G, Guadagni F.

Cancer. 2010 Jun 15;116(12):2913-21. doi: 10.1002/cncr.25094.

20.

Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.

Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M.

Cancer Biomark. 2009;5(4):167-75. doi: 10.3233/CBM-2009-0101.

PMID:
19729826
21.

Prognostic significance of serum adipokine levels in colorectal cancer patients.

Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P.

Anticancer Res. 2009 Aug;29(8):3321-7.

22.

Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer.

Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F.

Oncology. 2006;71(3-4):176-84. Epub 2007 Jul 23.

PMID:
17652942
23.

Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy.

Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V, Roselli M.

In Vivo. 2007 Mar-Apr;21(2):147-61. Review.

24.

Optimal dose of stereotactic radiosurgery for acoustic neuromas: A systematic review.

Weil RS, Cohen JM, Portarena I, Brada M.

Br J Neurosurg. 2006 Aug;20(4):195-202. Review.

PMID:
16954068
25.

Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients.

Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I, Mariotti S, Ambrogi V, Mineo TC, Roselli M.

Anticancer Res. 2005 Jan-Feb;25(1B):403-7.

26.

N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.

Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B, Graziani G.

Mol Pharmacol. 2005 Feb;67(2):572-81. Epub 2004 Nov 17.

PMID:
15548765
27.

Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.

Clin Cancer Res. 2003 Nov 1;9(14):5370-9.

28.

Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.

Graziani G, Tentori L, Portarena I, Vergati M, Navarra P.

Endocrinology. 2003 Jul;144(7):2822-8.

PMID:
12810536
29.

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.

Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.

Mol Pharmacol. 2003 Jan;63(1):192-202.

PMID:
12488552
30.
31.

Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.

Tentori L, Portarena I, Vernole P, Gold B, Graziani G.

Cancer Chemother Pharmacol. 2002 Mar;49(3):217-24. Epub 2002 Jan 22.

PMID:
11935214
32.

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.

Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G.

Blood. 2002 Mar 15;99(6):2241-4.

33.

CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway.

Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, Navarra P.

Endocrinology. 2002 Mar;143(3):807-13.

PMID:
11861501
34.

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

Tentori L, Portarena I, Graziani G.

Pharmacol Res. 2002 Feb;45(2):73-85. Review.

PMID:
11846617
35.

Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester.

Tentori L, Balduzzi A, Portarena I, Levati L, Vernole P, Gold B, Bonmassar E, Graziani G.

Cell Death Differ. 2001 Aug;8(8):817-28.

37.

Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

Tentori L, Portarena I, Vernole P, De Fabritiis P, Madaio R, Balduzzi A, Roy R, Bonmassar E, Graziani G.

Cancer Chemother Pharmacol. 2001 Apr;47(4):361-9.

PMID:
11345654
38.

Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells.

Tentori L, Vernole P, Lacal PM, Madaio R, Portarena I, Levati L, Balduzzi A, Turriziani M, Dande P, Gold B, Bonmassar E, Graziani G.

Leukemia. 2000 Aug;14(8):1451-9.

PMID:
10942242

Supplemental Content

Loading ...
Support Center